Avalo Therapeutics Inc

Avalo Therapeutics announced it will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston. The clinical stage biotechnology company is focused on developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Its lead asset is abdakibart, an anti-IL-1β monoclonal antibody that recently reported positive topline data from a Phase 2 trial in hidradenitis suppurativa. Avalo is also advancing AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody designed to extend dosing intervals.